

Curriculum Vitae

JOHAN E. S. SAMANTA, M.D.

Movement Disorders Neurologist

Diplomate of the ABPN

2610 N 3rd St, Suite A

Phoenix, AZ 85004

Phone: 602-277-2228

Fax: 602-265-9494

Tax ID: 86-1025375

CURRENT POSITION:

Director, Movement Disorders Research
Banner Good Samaritan Medical Center,
Phoenix, Arizona. June 2003

Clinical Associate Professor of Neurology
University of Arizona College of Medicine
Tucson, Arizona. November 2003

Clinical Faculty
Biodesign Institute at Arizona State University
Tempe, Arizona. February 2004

Co-Medical Director
American Parkinson's Disease Association (APDA),
Phoenix Chapter. April 2006

EDUCATION:

M.D., Medical College of Pennsylvania, Philadelphia,
Pennsylvania. August, 1991-May 1995

B.S., University of Michigan, Ann Arbor, Michigan
Major: Biology
Dean's List 1989-1991
September 1989-May 1991

University of Rochester, Rochester, New York
September 1987-July 1989
Dean's List 1988-1989
Student Government Representative 1987-1988

EXPERIENCE:

Associate Program Director of Neurology Residency, Barrow
Neurological Institute, Phoenix, Arizona. July 2001-June 2003

Staff Neurologist, Movement Disorders Section, Division of
Neurology, Barrow Neurological Institute, Phoenix, Arizona.
July 2000-June 2003

Evelyn Kossak Movement Disorders Fellow, Muhammad Ali Parkinson Research Center at Barrow Neurological Institute, Phoenix, Arizona. July 1, 1999-June 2000.

Resident in Neurology, Barrow Neurological Institute
Phoenix, Arizona. July 1, 1996-June 30, 1999

Medical Internship, St Joseph's Hospital and Medical Center
Phoenix, Arizona. July 1995-June 1996.

Surgical Technologist, C.S. Mott Children's Hospital, University
of Michigan Medical Center. 1990-1991.

Research Assistant, Mental Health Research Institute, University
of Michigan. 1988-1990.

MEDICAL LICENSURE: State of Arizona Medical License, 1997 - present

BOARD CERTIFICATION: Neurology, 2002

COMMITTEES/ASSOCIATIONS:

Movement Disorder Society, Member

American Academy of Neurology, Member

Arizona Neurological Society, Charter Member
Past Treasurer 2005-2007

We Move, Member

Parkinson's Study Group, Member

Parkinson's Disease Council Task Force, Member

RESEARCH: Merck KgaA. Principle Investigator: A double-blind, placebo-controlled multicenter study to evaluate the safety and efficacy of Sarizotan HCl 1mg b.i.d. in patients with Parkinson's disease suffering from treatment associated dyskinesias (PADDY-2). 2005-2006.

Schwarz Biosciences. Principle Investigator: A Multicenter, Multinational, Phase III, Randomized, Double-blind, Parallel group, Placebo-controlled Trial of the Efficacy and Safety of

Rotigotine, CDS Patch (2 target doses) in Subjects with Advanced Stage, Idiopathic Parkinson's Disease Who Are Not Well Controlled on Levodopa, 2002-current.

Schwarz Biosciences. Principle Investigator: A Multicenter, Multinational, Phase III, Randomized, Double-blind, Placebo - controlled Trial of the Efficacy and Safety of the Rotigotine CDS Patch in Subjects with Early Stage Idiopathic Parkinson's Disease, 2002-current.

Kyowa Pharmaceutical, Inc. Co-Investigator: A 12-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study of the Efficacy of Doses of 20 and 60 mg/day KW-6002 as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy, 2002-2003.

Kyowa Pharmaceuticals, Inc. Co-Investigator: A Long-Term, Multicenter, Open-Label, Safety Study with a Flexible Dose Range of KW-6002 as Treatment for Parkinson's Disease in Patients with Motor Response Complications on Levodopa/Carbidopa Therapy, 2002-2003.

Ortho-McNeil Pharmaceutical, Inc. Co-Investigator: A Comparison of the Efficacy and Safety of Topiramate versus Placebo in the Treatment of Essential Tremor, 2001-2002.

Baylor College of Medicine. Co-Investigator: Botulinum Toxin Type B Observational Study, 2001-2002.

Elan Pharmaceuticals, Inc. Co-Investigator: An Open-Label Safety and Immunogenicity Study of Myobloc™ (Neurobloc®, Botulinum Toxin Type B) Injectable Solution in Patients with Cervical Dystonia, 2001-2002.

Dystonia Study Group and Rush- Presbyterian St. Luke's Medical Center. Rating Investigator: A Randomized, Multi-Center, Double Blind, Parallel Group Study Comparing Botox® (Botulinum Toxin Type A) and Myobloc™ (Botulinum Toxin Type B) in Cervical Dystonia (CD) Subjects Responsive to Botulinum Toxin Type A, 2001-2002.

Parkinson Study Group and TEVA Pharmaceuticals, USA. Principal Investigator: A Bi-national, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Tolerability of Rasagiline Mesylate in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy, 2001-2004.

Parkinson Study Group and TEVA Pharmaceuticals, USA. Principal Investigator: Double-Blind, Randomized, Placebo-

Controlled, Parallel Group Study for the Efficacy, Tolerability, and Safety of Rasagiline Mesylate in Levodopa Treated Parkinson's Disease Patients, 2000-2003.

Novartis Pharmaceuticals. Principal Investigator: A Multicenter, Double-blind, Placebo-Controlled Study of the Tolerability and Effect of Entacapone in Parkinson's Subjects with End-of-dose Wearing-off Symptoms Occurring no Earlier than 4 Hours after their Most Recent Levodopa/Carbidopa Dose, 2000-2002.

Co-Investigator: "The Ali Project: Utility, Efficiency and Patient Acceptance of a Database Research Tool for Parkinson's Disease," 2000-2003.

Principal Investigator: Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson's Disease, 1999-2003.

Amgen, Inc. Co-Investigator: Randomized, Double-blind, Placebo-controlled, Parallel-group, 6-month Safety, Efficacy and Neuroimaging Trial of AMG-474-00 in the Treatment of Parkinson's Disease, 2000-2001.

Parkinson Study Group and Columbia University. Primary Rater: Earlier vs. Later Levodopa in Parkinson's Disease, 1998-2002.

Parkinson Study Group and TEVA Pharmaceuticals, USA. Co-Investigator: A Bi-national, Multicenter, Open-label Study to Evaluate the Safety and Tolerability of TV-1203/Carbidopa Dispersible Tablets in Advanced Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Chronic Levodopa/Carbidopa Therapy, 2000-2002.

Parkinson Study Group and TEVA Pharmaceuticals, USA. Co-Investigator: Randomized, Double-Blind, Double Dummy, Parallel Group Study Comparing TV-1203/Carbidopa Dispersible Tablets with Levodopa/Carbidopa Tablets in Advanced Parkinson's Disease Patients, 2000-2002.

Co-Investigator, Clomethiazole Acute Stroke Study in Ischemic Stroke, 1999.

Co-Investigator, Lobeluzole Acute Stroke Study, 1996-1998.

Changes at Multiple Levels of the Hypothalamo-pituitary Adrenal Axis Following Repeated Electrically Induced Seizures. Undergraduate research assistant, 1990. Mental Health Research Institute, University of Michigan. Principal Investigator: Dr. Elizabeth Young.

PUBLICATIONS:

Adler CH, Connor DJ, Sabbagh MN, Shill HA, Hentz JG, Evidente VGH, Mahant P, Samanta J, Burns RS, Ahmed A, Driver-Dunckley E, Vedders L, Noble B, Caviness JN. Parkinson's disease increases the risk for developing mild cognitive impairment. *Mov Disorders* 2008 23(Suppl 1):S100.

Frank MJ, Samanta J, Mustafa AA, Sherman SJ. Hold your horses: impulsivity, deep brain stimulation, and medication in parkinsonism. *Science*. 2007 Nov 23;318(5854):1309-12.

Caviness JN, Hentz JG, Evidente VGH, Driver-Dunckley ED, Samanta J, Mahant P, Connor DJ, Sabbagh MN, Shill HA, Adler CH. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. *Parkinsonism and Related Disorders* 2007 13:348-354.

Sabbagh MN, Lahti T, Connor DJ, Caviness JN, Shill H, Mahant P, Samanta J, Burns RS, Evidente VGH, Driver-Dunckley E, Reisberg B, Bircea S, Adler CH. Functional decline correlates with cognitive impairment in Alzheimer's disease and Parkinson's disease. *Dement Geriatr Cogn Disord* 2007;24:327-334

Samanta J, Hauser R. Duodenal levodopa infusion for the treatment of Parkinson's disease. *Expert Opin Pharmacother*. 2007 Apr;8(5):657-64.

Caviness JN, Hentz JG, Evidente VG, Driver-Dunckley E, Samanta J, Mahant P, Connor DJ, Sabbagh MN, Shill HA, Adler CH. Both early and late cognitive dysfunction affects the electroencephalogram in Parkinson's disease. *Parkinsonism Relat Disord*. 2007 Mar 7

Samanta J. Primary Generalized Dystonia, In: *Handbook of Dystonia*. Stacy MA (Ed.), Informa Healthcare, New York (2007): 107-120.

Samanta J, Hauser R. Levodopa/carbidopa/entacapone for the treatment of Parkinson's disease. *Aging Health* 2006;2:209-19.

Voon V, Krack P, Lang AE, Lozano AM, Dujardin K, Tamma F, Thobois S, Schupbach M, Samanta J, Kubu C, Poon Y, Saint-Cyr JA, Moro E. Frequency and risk factors for suicidal outcomes following subthalamic deep brain stimulation surgery for Parkinson's disease: a multicenter retrospective survey.

Abstract. 58th American Academy of Neurology 58th Annual Meeting. Neurology 2006; 65(Supp).

Mulligan S, Narayanan K, Mahant P, Samanta J, Abbas J. Effect of Deep Brain Stimulation on Posture Control in Parkinson's Disease. Abstract. 9th International Congress of Parkinson's Disease & Movement Disorders. 2005.

Driver-Dunckley E, Samanta J, Stacy M. Hypomania and Pathological Gambling Associated with Pramipexole Therapy in Parkinson's Disease. Neurology 2003;61:422-3.

Samanta J, Stacy M. Efficacy of Botulinum Toxin Type B (Myobloc™) in a Case of Hemifacial Spasm. Abstract. 7th International Congress of Parkinson's Disease & Movement Disorders, 2002.

Stacy M, Hauser R, Samanta J, Zesiewicz T, Sebade D, Cimino C. The Total Functional Capacity Scale: A Useful and Rapid Assessment Tool for Monitoring Parkinson disease Disability. Abstract. 7th International Congress of Parkinson's Disease & Movement Disorders, 2002.

Thomas K, Samanta J, Mahant P, Williamson K, Stacy M. The Ali Project: a web-based database for Parkinson's disease. Abstract. 7th International Congress of Parkinson's Disease & Movement Disorders, 2002.

Samanta J, Stacy M. Efficacy of Botulinum Toxin Type B (Myobloc™) for Treatment of Blepharospasm: Report of two Cases. Abstract. 7th International Congress of Parkinson's Disease & Movement Disorders, 2002.

Baev K, Greene A, Marciano F, Samanta J, Shetter A, Smith K, Stacy M, Spetzler R. Physiology and pathophysiology of cortico-basal ganglia-thalamocortical loops: Theoretical and practical aspects. Neuro-Psychopharmacology & Biological Psychiatry 2002, 26:771-804.

Samanta J. Activa Therapy: Myths & Misconceptions. Synapses: Medtronic Newsletter 2002, 5:2.

Stacy M, Drumm D, Samanta J, Williamson K, Mahant P, Shetter A. Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson's Disease. 125th Annual Meeting of the American Neurological Association, 2000.

Samanta J, Stacy M. Compulsive Gambling in Dopaminergic Therapy in Parkinson's Disease. Abstract. Sixth International Congress of Parkinson's Disease and Movement Disorders, 2000.

Samanta J. Parkinson's at Night. Southwest Parkinson's Report, 2000.

Samanta J, Stacy M. Quetiapine in the treatment of hallucinations in advanced Parkinson's Disease. Abstract. Fifth International Congress of Parkinson's Disease and Movement Disorders, 1998.

Revised 02/22/08